$TKNO

Alpha Teknova, Inc.

1
0
0

No SEC Form 4 filings for $TKNO in the last 30 days.

See all $TKNO insider activity →
Low

Teknova Unveils Fill-Tek For Customized Single-Use Reagent Orders

Alpha Teknova (TKNO) launched Fill-Tek, a system for custom single-use bag filling, offering flexibility in sizes, quantities, and testing. The system supports 250 mL to 200 L bags and is available immediately. TKNO's stock closed at $7.11, up 3.04%, and is at $7.50 in pre-market trading.

Alpha Teknova Raises Outlook After Record Q2 Revenue at Sidoti Conference

Alpha Teknova (NASDAQ: TKNO) raised its outlook after reporting record Q2 revenue. The company expects to become adjusted EBITDA-positive in 2027 with revenue between $52M and $57M. Key growth drivers include customer progression to higher-value products and increased biopharma funding. Teknova also plans to invest in commercial capabilities and evaluate bolt-on acquisitions.

Here are Tuesday's biggest analyst calls: SpaceX, Nvidia, Tesla, Apple, Best Buy, Boeing, First Solar & more

A roundup of Wall Street analyst actions includes UBS upgrading Jabil to Buy, initiating Lincoln Electric and Century Aluminum with price targets, and Bernstein initiating PDF Solutions. JPMorgan reiterates Nvidia overweight and raises CoreWeave to $110. Other changes include Loop lowering Apple to $340, Truist upgrading Best Buy to $95, and Argus upgrading Boeing to buy.

TKNO sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning TKNO (Alpha Teknova, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.

Recent TKNO coverage spans financial news, earnings and technology.

What's driving TKNO

  • The new system could increase addressable market share and improve revenue visibility for Teknova.

    rttnews.com · Sep 17, 2026

  • Positive guidance may lift the stock as investors price in higher future profitability.

    yahoo.com · Aug 21, 2026

  • Upgrade is supported by a specific recent beat and guidance raise, making it more fundamental than pure sentiment.

    cnbc.com · Aug 11, 2026

  • The article frames a demand rebound for Alpha Teknova’s life-science reagents, anchored to a reported 85% revenue increase in Clinical Solutions.

    insidermonkey.com · Aug 7, 2026

  • Guidance raise plus improved cash outflow outlook is a near-term positive catalyst for TKNO’s valuation and risk profile.

    SEC EDGAR 8-K · Aug 5, 2026

AlphAI scores every news story that mentions TKNO with an AI model for sentiment and relevance, and aggregates insider trades from Alpha Teknova, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $TKNO

Score
$TKNOMed

Alpha Teknova Raises Outlook After Record Q2 Revenue at Sidoti Conference

Alpha Teknova (NASDAQ: TKNO) raised its outlook after reporting record Q2 revenue. The company expects to become adjusted EBITDA-positive in 2027 with revenue between $52M and $57M. Key growth drivers include customer progression to higher-value products and increased biopharma funding. Teknova also plans to invest in commercial capabilities and evaluate bolt-on acquisitions.

$JBLMed

Here are Tuesday's biggest analyst calls: SpaceX, Nvidia, Tesla, Apple, Best Buy, Boeing, First Solar & more

A roundup of Wall Street analyst actions includes UBS upgrading Jabil to Buy, initiating Lincoln Electric and Century Aluminum with price targets, and Bernstein initiating PDF Solutions. JPMorgan reiterates Nvidia overweight and raises CoreWeave to $110. Other changes include Loop lowering Apple to $340, Truist upgrading Best Buy to $95, and Argus upgrading Boeing to buy.

Alpha Teknova (TKNO) Stock Moves Higher on Booming Clinical Demand

Conestoga Capital Advisors’ Q2 2026 investor letter highlighted a shift toward small caps, citing Russell 2000 and Russell 2000 Growth gains. The letter said Alpha Teknova (NASDAQ:TKNO) was a top contributor, with shares at $6.53 on Aug. 6, 2026, and Clinical Solutions revenue up 85%, supported by improving biotech funding and customer activity.

$TKNOHigh

Alpha Teknova, Inc. (TKNO): Results of Operations and Financial Condition

Alpha Teknova, Inc. (TKNO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Teknova Reports Second Quarter 2026 Financial Results Second quarter 2026 total revenue was $12.2 million, up 18% over the same quarter prior year Company raises 2026 revenue guidance to $45-47 million Launched proprietary AI-powered Build-Tek TM custom order configu

$BMYMed

Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls

Analyst actions highlighted: Argus upgraded Bristol Myers (BMY) to Buy, $75 target, citing margin improvement and raised 2026 guidance. Freedom Broker upgraded McDonald's (MCD) to Buy, $305 target, on softer revenue and comps. Morgan Stanley upgraded Humana (HUM) to Equal Weight, $370 target. Jefferies downgraded Best Buy (BBY) to Hold, $85 target. Others included upgrades/downgrades for several stocks with updated price targets.

$TKNOMed

Alpha Teknova (TKNO) Q2 Revenue Jumps 7%

Alpha Teknova ( NASDAQ:TKNO ) , a specialist in custom bioprocess solutions for the life sciences sector, released its results on August 7, 2025. The most important news: Revenue ( GAAP ) rose by 7%, reaching $10.3 million, and net loss per share ( GAAP ) narrowed to $0.07, both of which ( GAAP ) ...

Related tickers